Abstract 12727: The Clinical Impact of Eicosapentaenoic Acid/Arachidonic Acid Ratio in Adult Patients With Congenital Heart Disease

Background: Recent studies showed that intake of long-chain n-3 polyunsaturated fatty acids reduces the incidence of cardiovascular events. Furthermore, low levels of eicosapentaenoic acid (EPA) are associated with heart failure (HF), arrhythmia, and cardiac sudden death. However, there have been few studies regarding the clinical implication of the EPA/arachidonic acid (AA) ratio in adult patients with congenital heart disease (CHD). Objectives and methods: The present study was a prospective study of 64 adult patients with CHD. We measured serum EPA and AA and divided the patients into two groups according to their EPA/AA ratio: Results: There were no significant differences between the low (n = 36) and high (n = 28) groups in age, sex, blood pressure, systemic ventricular ejection fraction, medications, or serum levels of hemoglobin A1c, creatinine, low-density lipoprotein-cholesterol, high-density lipoprotein-cholesterol, triglyceride, or B-type natriuretic peptide. A low EPA/AA ratio had significant prognostic value for arrhythmia (hazard ratio [HR] 3.6, 95% confidence interval [CI] 1.1-14.8, p = 0.03) and composite events of arrhythmia and HF hospitalization (HR 5.6, 95% CI 1.53-27.8, p Conclusions: The EPA/AA ratio had a significant predictive value for cardiac events in adult patients with CHD, especially in patients with two-ventricle circulation. The effect of EPA treatment for patients with CHD should be elucidated in the future.